The National Comprehensive Cancer Network (NCCN) has recognizing the increased sensitivity and specificity of PSMA- PET compared to conventional imaging (CT, MRI, bone scans) for detecting micrometastatic disease, at both initial staging and biochemical recurrence.

In new guidelines announced in September 2021, the NCCN no longer recommends conventional imaging as a necessary prerequisite to PSMA-PET; in fact, the NCCN’s panel states, “PSMA-PET/CT or PSMA-PET/MRI can serve as equally effective, if not more effective front- line imaging tools for these patients.”

In one fell swoop, PSMA-PET is changing the standard of care.